Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development

Reuters

2025/08/18

Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development

Klotho Neurosciences, Inc., a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, announced a significant regulatory milestone with the receipt of Orphan Drug Designation from the FDA for its gene therapy candidate, KLTO-202, aimed at treating Amyotrophic Lateral Sclerosis (ALS). This designation underscores the therapeutic potential of Klotho's innovative programs to address pressing unmet medical needs in the neurodegenerative disease market, which is valued at over $8 billion annually. The company's strategic advancements, including key partnerships and expanded research capabilities, are poised to accelerate the development and clinical evaluation of its promising therapeutic candidates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53130) on August 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2560402907"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560402907\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560402907?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-18 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560402907","market":"us","top_or_hot":-1,"title":"Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KLTO\">Klotho Neurosciences, Inc.</a>, a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, announced a significant regulatory milestone with the receipt of Orphan Drug Designation from the FDA for its gene therapy candidate, KLTO-202, aimed at treating Amyotrophic Lateral Sclerosis (ALS). This designation underscores the therapeutic potential of Klotho's innovative programs to address pressing unmet medical needs in the neurodegenerative disease market, which is valued at over $8 billion annually. The company's strategic advancements, including key partnerships and expanded research capabilities, are poised to accelerate the development and clinical evaluation of its promising therapeutic candidates.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53130) on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKlotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-18 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KLTO\">Klotho Neurosciences, Inc.</a>, a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, announced a significant regulatory milestone with the receipt of Orphan Drug Designation from the FDA for its gene therapy candidate, KLTO-202, aimed at treating Amyotrophic Lateral Sclerosis (ALS). This designation underscores the therapeutic potential of Klotho's innovative programs to address pressing unmet medical needs in the neurodegenerative disease market, which is valued at over $8 billion annually. The company's strategic advancements, including key partnerships and expanded research capabilities, are poised to accelerate the development and clinical evaluation of its promising therapeutic candidates.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53130) on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL3LV5ZQ:1","article_id":"2560402907","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560402907","pubTimestamp":1755520268,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development. Klotho Neurosciences, Inc., a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, announced a significant regulatory milestone with the receipt of Orphan Drug Designation from the FDA for its gene therapy candidate, KLTO-202, aimed at treating Amyotrophic Lateral Sclerosis . This designation underscores the therapeutic potential of Klotho's innovative programs to address pressing unmet medical needs in the neurodegenerative disease market, which is valued at over $8 billion annually. The company's strategic advancements, including key partnerships and expanded research capabilities, are poised to accelerate the development and clinical evaluation of its promising therapeutic candidates.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KLTO":"Klotho Neurosciences, Inc."},"translate_title":"Klotho Neuroscience Inc.获得FDA ALS治疗孤儿药指定，推进基于Klotho的治疗开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KLTO":0.9},"content_text":"Klotho Neuroscience Inc. Secures FDA Orphan Drug Designation for ALS Treatment, Advancing Klotho-Based Therapeutic Development\n    \n\nKlotho Neurosciences, Inc., a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, announced a significant regulatory milestone with the receipt of Orphan Drug Designation from the FDA for its gene therapy candidate, KLTO-202, aimed at treating Amyotrophic Lateral Sclerosis (ALS). This designation underscores the therapeutic potential of Klotho's innovative programs to address pressing unmet medical needs in the neurodegenerative disease market, which is valued at over $8 billion annually. The company's strategic advancements, including key partnerships and expanded research capabilities, are poised to accelerate the development and clinical evaluation of its promising therapeutic candidates.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53130) on August 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}